Liquid biopsy, also known as ctDNA, is emerging as a complementary technique to NGS. Liquid biopsy is being explored to screen for cancers, diagnose cancers, monitor for progression or relapse, and direct therapy selection. Studies have shown that liquid biopsy, with a broader view of systemic tumor evolution, can yield valuable information for certain tumor types that might be missed with localized tissue biopsy. Recent advances in NGS technology enable comprehensive genomic profiling combined with the sensitivity and specificity required for liquid biopsy applications.
Learn more about liquid biopsy with NGS technology.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer - Medscape - Aug 22, 2022.